ArticleCureus2023
Sonographic Assessment of Axillary Lymph Nodes Post COVID-19 Vaccine.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The development of axillary lymphadenopathy post COVID-19 vaccine became an area of concern. This needs to be addressed and investigated to provide updated data that could contribute to its management and imaging guidelines. Objectives This study aims to detect possible changes in lymph nodes (LNs) after COVID-19 vaccination, decrease the rate of over-investigation and medical costs, and identify possible predisposing factors that could trigger the development of lymphadenopathy. Methods This was a retrospective cohort study conducted in King Fahad University Hospital, a secondary hospital in Al Khobar, Kingdom of Saudi Arabia (KSA), on a total of 1,257 vaccinated patients who underwent axillary ultrasonography (US) from December 2020 till the second of October 2022. All required data were collected using an Excel sheet and analyzed using Statistical Product and Service Solutions (SPSS, version 21) (IBM SPSS Statistics for Windows, Armonk, NY). Results Out of the 1183 cases, 460 (38.9%) cases had abnormal LNs post COVID-19 vaccine based on US, while LNs were normal in 723 (61.1%) cases. The prevalence of axillary lymphadenopathy was significantly more common in females than males (39.1% of cases in female patients versus 22.2% of cases in male patients (P = 0.049)). In addition, lymphadenopathy was more prevalent among patients who received the COVID-19 vaccine less than four weeks ago, compared to others who received the vaccine four to eight weeks ago, 8-12 weeks ago, and more than 12 weeks ago (100% vs 73.3% vs 34.2% vs 72% (P = 0.001)). Conclusion In conclusion, a significant number of patients were found to have lymphadenopathy after receiving the COVID-19 vaccine. The only predisposing factors identified to be associated with the development of lymphadenopathy were gender (females more than males) and duration since receiving the vaccine (four weeks).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.